DeepMed Research

GENENTECH, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1976-01-01

Employees: 11.1K

Market Cap: -

Website: http://www.gene.com

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Phase 2

Active, not recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo
Drug: Astegolimab

First Posted Date: 2021-09-08

Last Posted Date: 2025-03-03

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 1334

Registration Number: NCT05037929

Locations: 🇧🇬
Medical Center Hera EOOD, Sofia, Bulgaria
🇨🇱
Centro de Investigacion del Maule, Talca, Chile
🇩🇪
Praxis Dr. Med Evelin Liefring, Berlin, Germany

and more 167 locations

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Cevostamab
Drug: Tocilizumab
Drug: Dexamethasone
Drug: Pomalidomide
Drug: Daratumumab

First Posted Date: 2021-06-02

Last Posted Date: 2025-04-13

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 126

Registration Number: NCT04910568

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
City of Hope - Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸
Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado, United States

and more 27 locations

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration(nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Phase 4

Recruiting

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Device: SUSVIMO PDS Implant
Drug: LUCENTIS (ranibizumab injection)

First Posted Date: 2021-04-21

Last Posted Date: 2025-05-13

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 188

Registration Number: NCT04853251

Locations: 🇺🇸
Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸
California Retina Consultants, Bakersfield, California, United States
🇺🇸
Retina Associates of Southern California, Huntington Beach, California, United States

and more 46 locations

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Phase 1

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Belvarafenib
Drug: Cobimetinib
Drug: Nivolumab

First Posted Date: 2021-04-08

Last Posted Date: 2025-03-25

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 65

Registration Number: NCT04835805

Locations: 🇺🇸
California Pacific Medical Center Research Institute, San Francisco, California, United States
🇺🇸
UCSF Helen Diller Family CCC, San Francisco, California, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

and more 11 locations

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [14C]-GDC-9545
Drug: GDC-9545 Solution for Infusion
Drug: GDC-9545/F12 Capsule
Drug: GDC-9545/F18 Capsule

First Posted Date: 2020-12-22

Last Posted Date: 2023-02-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 16

Registration Number: NCT04680273

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Phase 2

Completed

Conditions: Advanced Unresectable or Metastatic Solid Malignancy

Interventions: Drug: Entrectinib
Drug: Inavolisib
Drug: Alectinib
Drug: Ipatasertib
Drug: Atezolizumab
Drug: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
Drug: Pralsetinib
Drug: Investigator's Choice of Chemotherapy
Drug: Trastuzumab Emtansine
Drug: Tucatinib
Drug: Paclitaxel
Drug: Tiragolumab

First Posted Date: 2020-11-17

Last Posted Date: 2025-01-08

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 252

Registration Number: NCT04632992

Locations: 🇺🇸
Sarah Cannon Research Institute / Tennessee Oncology, Chattanooga, Tennessee, United States
🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸
Alaska Oncology and Hematology, Anchorage, Alaska, United States

and more 35 locations

A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Phase 2

Terminated

Conditions: Macular Degeneration, Age-Related
Geographic Atrophy

Interventions: Drug: Galegenimab

First Posted Date: 2020-10-29

Last Posted Date: 2023-10-16

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 144

Registration Number: NCT04607148

Locations: 🇺🇸
Southwest Retina Consultants, Durango, Colorado, United States
🇺🇸
Florida Eye Associates - Melbourne 2nd Office, Melbourne, Florida, United States
🇺🇸
Southeastern Retina Associates Chattanooga, Chattanooga, Tennessee, United States

and more 44 locations

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer Disease (AD)

Interventions: Drug: [18F]GTP1
Drug: [18F]MK-6240
Drug: [18F]PI-2620

First Posted Date: 2020-09-28

Last Posted Date: 2023-07-12

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 40

Registration Number: NCT04566003

Locations: 🇺🇸
Invicro, a Konica Minolta company, New Haven, Connecticut, United States

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1

Completed

Conditions: Acute Graft-versus-host Disease

Interventions: Drug: Efmarodocokin Alfa

First Posted Date: 2020-09-07

Last Posted Date: 2024-04-11

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 18

Registration Number: NCT04539470

Locations: 🇺🇸
University of Kansas Med Ctr; Int med/Allgy/Immun/Rheum, Kansas City, Kansas, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

and more 5 locations

A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: BLYG8824A

First Posted Date: 2020-07-13

Last Posted Date: 2025-04-25

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 46

Registration Number: NCT04468607

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇪🇸
Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy